We are advising Roche on the acquisition

Davis Polk is advising Roche on its acquisition of select parts of the LumiraDx group related to LumiraDx group’s innovative point of care technology platform. Roche will make the acquisition as part of a pre-packaged U.K. administration sale, with the full support of the LumiraDx group’s senior secured lender. Roche will pay a purchase price of $295 million, subject to customary closing adjustments, and an additional payment of up to $55 million for the reimbursement of amounts required to fund the point of care technology platform prior to the acquisition closing. The transaction is subject to certain closing conditions, including antitrust and regulatory approvals, and is expected to close by mid-2024. The acquired entities will be fully integrated into Roche Diagnostics following closing.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

LumiraDx is a U.K.-based next-generation point of care diagnostics company that is transforming community-based healthcare.

The Davis Polk corporate team includes partners Will Pearce and Brian Wolfe, counsel Joseph Scrace and associates Andrew R. Board and Gilbert Lim. Partner David R. Bauer and associates Yana Kipnis and Adrian Rabin are providing intellectual property advice. Partner Dominic Foulkes and associate Freddie Schwier are providing tax advice. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post